文献速递消化道肿瘤放疗

食管或胃食管结合部癌术前放化疗:扩展CROSS方案回顾性研究

Preoperative chemoradiotherapy for esophageal or gastroesophageal junction cancer: results from a retrospective study using extended CROSS regimen.
PubMed 文献 · Radiat Oncol · 2025-05-08

该回顾性观察研究纳入2014至2018年46例接受改良新辅助放化疗(50.4 Gy/28次联合每周卡铂/紫杉醇)后手术的食管癌患者,评估肿瘤学结局、毒性和病理完全缓解率。病理完全缓解率为16.7%,中位生存期2.7年,多变量分析显示病理完全缓解与更低死亡风险相关,较大放疗体积呈非显著死亡风险升高趋势。结论认为剂量提升至50.4 Gy未较CROSS试验提高病理完全缓解率或生存获益。

要点

  • 改良方案为50.4 Gy/28次联合每周卡铂/紫杉醇,病理完全缓解率16.7%。
  • 病理完全缓解与显著降低的死亡风险相关(OR 0.152,95%CI 0.049-0.989,p=0.048)。
  • 较大放疗体积呈非显著死亡风险升高趋势(每100单位OR 1.172,95%CI 0.987-1.392)。

核心结论

  • 食管癌接受三联治疗时,放疗剂量提升至50.4 Gy未较CROSS试验结果提高病理完全缓解率或带来生存获益。
  • 多变量分析显示较大放疗体积呈死亡风险升高趋势,但未达统计学显著。

研究设计与样本

  • 回顾性观察研究,纳入2014至2018年单中心三级大学医院接受新辅助放化疗后肿瘤切除的食管癌患者46例。
  • 改良放疗为28次×1.8 Gy(总50.4 Gy)联合每周卡铂/紫杉醇。
  • 采用多变量Cox回归分析病理完全缓解和放疗强度对死亡的影响,校正性别、年龄、ASA评分、肿瘤和淋巴结分期及组织学类型。

主要发现

  • 中位年龄67岁(IQR 9),男性36例(78.3%),ASA评分≥3者占90.7%。
  • 临床T分期≥3者38例(82.6%),超声内镜淋巴结阳性(uN+)者42例(91.3%)。
  • 病理完全缓解7/42例(16.7%),中位生存期2.7年(95%CI 1.340-4.084)。
  • 多变量Cox回归中病理完全缓解与显著更低死亡风险相关(OR 0.152,95%CI 0.049-0.989,p=0.048)。
  • 较大放疗体积呈死亡风险升高趋势但无统计学意义(放疗体积/100:OR 1.172,95%CI 0.987-1.392)。

临床怎么用

  • 基于该结果,使用在线自适应放疗等现代放疗技术可能比单纯提升放疗剂量更有益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The standard of care for locally advanced esophageal cancer includes perioperative chemotherapy or neo-adjuvant chemo-radiotherapy (CRT), followed by surgery. At our institution, a modified neo-adjuvant regimen combining elements from CROSS and CALGB 9781 trials was adopted. This study aimed to assess the impact of our modified regimen on oncological outcomes, toxicity profile and pathological complete response rates compared to the CROSS trial. METHODS: This observational study included patients with esophageal cancer who underwent neo-adjuvant CRT followed by tumor resection at a tertiary care university hospital between 2014 and 2018. The modified radiation therapy consisted of 28 fractions of 1.8 Gy (50.4 Gy in total) with weekly carboplatin/paclitaxel. We assessed mortality over time using the median survival time. The impact of pathological complete response and radiation intensity on mortality was assessed in multivariable Cox regression analysis, adjusting for clinically relevant variables, including sex, age, American Society of Anesthesiologists (ASA) physical status classification system score, tumor and nodal stage, and the histological tumor type. RESULTS: A total of 46 patients were included. Median age was 67 years (IQR 9), 36 patients (78.3%) were male. An ASA score ≥ 3 was reported in 90.7% of the patients. Among the patients, 38 (82.6%) had a clinical tumor stage (cT) of ≥ 3, and 42 (91.3%) showed a positive endo-sonographic nodal stage (uN+). Pathological complete response was found in 7/42 patients (16.7%). Median survival time was 2.7 years (95% CI 1.340-4.084). In multivariable Cox regression analysis, pathological complete response was associated with significantly lower mortality over time (OR 0.152, 95%CI 0.049-0.989, p = 0.048). For larger radiation volumes, a trend towards increased mortality was shown, although not statistically significant (radiation volume/100: OR 1.172, 95%CI 0.987-1.392). CONCLUSIONS: In patients with esophageal cancer undergoing trimodal therapy, the radiation dose escalation to 50.4 Gy was not associated with higher rates of pathological complete response or a survival benefit compared to the results of the CROSS trial. However, multivariable analysis revealed a trend toward increased mortality with larger radiation volumes. Based on these results, using modern radiotherapy techniques such as online adaptive radiotherapy might be more beneficial instead of escalating the radiation dose.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Haltmeier T, Brazerol J, Borbely Y, et al. Preoperative chemoradiotherapy for esophageal or gastroesophageal junction cancer: results from a retrospective study using extended CROSS regimen. Radiat Oncol. 2025. PMID: 40341043. doi:10.1186/s13014-025-02637-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。